1. DaVita reported $3.224 billion in revenues for Q1 2025. 2. Diluted earnings per share decreased to $2.00 from $3.09 in Q4 2024. 3. Operating income fell to $439 million, down from $565 million last quarter. 4. $550 million were used to repurchase shares at an average price of $148.94. 5. Dialysis treatments were stable, with a slight year-over-year decline of 0.6%.
The financial results showed revenue stability; however, decreased earnings and income can pressure stock value. Historically, similar earnings drops have led to stagnation or slight declines.
The release of quarterly results is significant and reflects operational health; however, mixed indicators temper the expected market reaction.
Recent performance could lead to short-term stock fluctuations, especially as market reacts to quarterly results.
DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2025.
"Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders."
| Three Months Ended | March 31, 2025 | December 31, 2024 | March 31, 2024 |
|---|---|---|---|
| Net income attributable to DaVita Inc. (dollars in millions) | $163 | $259 | $240 |
| Diluted per share | $2.00 | $3.09 | $2.65 |
| Adjusted net income | $163 | $188 | $205 |
| Adjusted diluted per share | $2.00 | $2.24 | $2.26 |
Total U.S. dialysis treatments for the first quarter of 2025 were 7,040,519, or an average of 91,793 treatments per day, representing a per day increase of 0.01% compared to the fourth quarter of 2024.
The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, and actual results may vary materially from these forward-looking measures.
| Measure | Low | High |
|---|---|---|
| Adjusted operating income | $2,010 | $2,160 |
| Adjusted diluted net income per share | $10.20 | $11.30 |
| Free cash flow | $1,000 | $1,250 |
Investor Relations
DaVita Inc.
Source: DaVita